We intend to focus our investment efforts broadly across the entire health care industry, which encompasses among other things technology-enabled services, biopharmaceuticals, pharmaceutical value chain, medical devices, diagnostics, providers, digital health and consumer health. We will seek to capitalize on the more than 50 years of combined investing experience of our founders, James C. Momtazee and Maria C. Walker.

Mr. Momtazee has over 23 years of investment and acquisition experience. He will serve as the CEO and president of our company and chairman of the board of directors. He initially joined KKR & Co., Inc., or KKR, in 1996. He helped form the health care industry group in 2001. During the period between 2001 and 2019, KKR was one of the most active investors on Wall Street, committing over $50 billion in capital, across the health care sector. The largest of these investments was its $33 billion acquisition of HCA, Inc. in 2006, which at the time, was the largest cash buyout in history.

Ms. Walker has over 30 years of operational and investment experience. She will serve as the CFO of our company. Most recently, She co-founded, and served as CEO of Recuerdo Therapeutics, a biotechnology startup that focused on the postponement of Alzheimer’s disease. Before her time with Recuerdo, Ms. Walker spent the majority of her career with KPMG where, over two separate periods between 1993 to 2000 and 2008 to 2018, she advanced to the role of senior partner and served as a global lead partner of private equity.